Wound wash saline comment
This article was originally published in The Tan Sheet
Executive Summary
FDA's proposal to declare wound wash saline products unapproved new drugs is misguided, given the agency's history of regulating wound cleansers as medical devices, the Washington office of King & Spalding says in a Sept. 16 letter to FDA. In a June 19 Federal Register notice, the agency includes wound wash saline in a list of drug ingredients and products proposed to not be generally recognized as safe and effective and to require an approved new drug application for future marketing (1"The Tan Sheet" June 23, 2008, p. 7). Since the Center for Devices and Radiological Health regards such sterile wash products as functioning through a physical mechanism rather than chemical or metabolic action, King & Spalding encourages FDA to clarify in a final rule "that not all 'wound wash saline' products are 'drugs,' much less 'new drugs.'
You may also be interested in...
FDA Proposes Aloe Vera, Other Ingredients For Non-GRASE List
FDA has proposed adding aloe vera products labeled for analgesic and antimicrobial uses to its list of ingredients and categories that lack adequate data to establish their safety and effectiveness
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.